High Intensity Interval Exercise SCI
Telehealth High Intensity Interval Exercise and Cardiometabolic Health in Spinal Cord Injury
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gordon Fisher, PhD
- Phone Number: 2059964114
- Email: Grdnfs@uab.edu.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women, 19-65 years of age.
- Confirmed diagnosis of traumatic SCI at the cervical or thoracic level (C7-T12), classified as A, B, C, or D (motor and sensory complete or incomplete) on the AIS scale.
- At least 6 months post-injury.
- Able to independently operate an arm ergometer.
- Have access to a wireless internet connection.
- Medically stable, able to provide informed consent.
Exclusion Criteria:
- Cardiovascular or renal diseases.
- Pregnant women
- Orthopedic conditions that prevents arm ergomtery
- Upper extremity musculoskeletal conditions that prevents arm ergometry.
- Neurological disorder that prevents arm ergometry
- Participation in a structured exercise program currently or in the past 3 months.
Unable to perform exercise interventions
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: High intensity interval exercise
High intensity interval arm crank exercise
|
HIIT training will be delivered two times per week for 16 weeks (32 sessions).
Each session will be separated by at least 24-hrs.
Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule.
The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test.
HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
|
|
Other: No-Exercise Control
No-exercise control group
|
No-exercise control group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Aerobic Capacity Baseline
Time Frame: baseline
|
All subjects will undergo a progressive peak oxygen assessment to determine aerobic capacity at the Lakeshore Foundation Exercise Physiology Facility.
Subjects will be instructed to perform arm crank ergometer (Lode) at 10W for 2 min.
Every 2 min thereafter, power output will be increased by 10W until voluntary fatigue.
Peak aerobic power will be defined as VO2 at the point of failure to maintain 60-65 rotations per minute.
|
baseline
|
|
Aerobic Capacity Week 16
Time Frame: 16weeks post training
|
All subjects will undergo a progressive peak oxygen assessment to determine aerobic capacity at the Lakeshore Foundation Exercise Physiology Facility.
Subjects will be instructed to perform arm crank ergometer (Lode) at 10W for 2 min.
Every 2 min thereafter, power output will be increased by 10W until voluntary fatigue.
Peak aerobic power will be defined as VO2 at the point of failure to maintain 60-65 rotations per minute.
|
16weeks post training
|
|
Matsuda Index Baseline
Time Frame: baseline
|
Oral glucose tolerance test.
Following an overnight fast each subject will consume a 75g oral glucose load within 5 min.
Blood samples will be collected immediately before and 60, 90, and 120 min following glucose ingestion for measurement of serum glucose and serum insulin.
Insulin sensitivity was calculated using glucose and insulin values by the Matsuda Index, in which a higher number demonstrates an improvement in insulin sensitivity,
|
baseline
|
|
Matsuda Index Week 16
Time Frame: 16weeks post training
|
Oral glucose tolerance test.
Following an overnight fast each subject will consume a 75g oral glucose load within 5 min.
Blood samples will be collected immediately before and 60, 90, and 120 min following glucose ingestion for measurement of serum glucose and serum insulin.
Insulin sensitivity was calculated using glucose and insulin values by the Matsuda Index, in which a higher number demonstrates an improvement in insulin sensitivity,
|
16weeks post training
|
|
Cholesterol Baseline
Time Frame: baseline
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
baseline
|
|
Cholesterol Week 16
Time Frame: 16weeks post training
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
16weeks post training
|
|
Body Composition Baseline
Time Frame: baseline
|
Dual-energy X-ray absorptiometry (DXA).
Percent Body Fat
|
baseline
|
|
Body Composition Week 16
Time Frame: 16weeks post training
|
Dual-energy X-ray absorptiometry (DXA).
Percent Body Fat
|
16weeks post training
|
|
Triglycerides Baseline
Time Frame: baseline
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
baseline
|
|
Triglycerides Week 16
Time Frame: 16-weeks post
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
16-weeks post
|
|
HDL Baseline
Time Frame: Baseline
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
Baseline
|
|
HDL Week 16
Time Frame: 16-weeks post training
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
16-weeks post training
|
|
LDL Baseline
Time Frame: Baseline
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
Baseline
|
|
LDL Week 16
Time Frame: 16-weeks post training
|
Laboratory analyses.
Concentrations of blood lipids will be determined in the Core Laboratory of the CCTS, NORC, and DRC.
|
16-weeks post training
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Semi-Structured Interview
Time Frame: 16 weeks post-training
|
The semi-structured interviews will contain seven open-ended questions related to the following areas: 1) overall perceptions of the program, 2) program likes, 3) dislikes, 4) perceived satisfaction and 5) value, 6) technology and equipment usability, and 7) factors that affected adherence.
These areas will be probed in greater detail by the interviewer through additional follow-up questions.
|
16 weeks post-training
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gordon Fisher, PhD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 000526083
- R21NR019309 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.